pSivida Corp (PSDV)

3.78
NASDAQ : Health Care
Prev Close 3.78
Day Low/High 0.00 / 0.00
52 Wk Low/High 2.37 / 5.81
Avg Volume 71.80K
Exchange NASDAQ
Shares Outstanding 34.17M
Market Cap 114.82M
EPS 0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Investigator-Sponsored Phase 2 Study Results Show PSivida's Medidur® Fully Controlled Uveitis For Two Years With No Recurrence Of Disease While Visual Acuity Continued To Improve

Investigator-Sponsored Phase 2 Study Results Show PSivida's Medidur® Fully Controlled Uveitis For Two Years With No Recurrence Of Disease While Visual Acuity Continued To Improve

Study Results Showing No Recurrence of Disease and Statistically Significant Improvement in Visual Acuity to be Published in Ophthalmology

PSivida Closes $17.8 Million Offering

PSivida Closes $17.8 Million Offering

Today's Weak On High Volume Stock: PSivida (PSDV)

Today's Weak On High Volume Stock: PSivida (PSDV)

Trade-Ideas LLC identified pSivida (PSDV) as a weak on high relative volume candidate

Trade-Ideas: PSivida (PSDV) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: PSivida (PSDV) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified pSivida (PSDV) as a strong on high relative volume candidate

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABBV, ACHN, DBD, DFS, GBLI, IFON, JOBS, LCUT, LOJN, NTL, RAIL, STT, TTWO, UVV Downgrades: AAWW, ASPN, BCH, ECPG, ETE, GSL, LPG, LXU, MW, MYRG, NTK, PCYO, PSDV, SEB, TNGO Initiations: RWLK, TPH, VTAE Read on to get TheStreet Quant Ratings' detailed report:

PSivida Announces NDA For Medidur™ Now Planned Using Six-Month Efficacy Data From Both Phase III Trials; FDA Concurs

PSivida Announces NDA For Medidur™ Now Planned Using Six-Month Efficacy Data From Both Phase III Trials; FDA Concurs

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, announced that the Company now plans to file a New Drug Application (NDA) for Medidur...

PSivida CEO To Present At Ladenburg Thalmann 2015 Healthcare Conference September 29, 2015

PSivida CEO To Present At Ladenburg Thalmann 2015 Healthcare Conference September 29, 2015

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that Dr.

PSivida Corp. Provides Company Update And Reports Fourth Quarter And FY 2015 Results

PSivida Corp. Provides Company Update And Reports Fourth Quarter And FY 2015 Results

pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today provided a Company update and announced financial results for its fourth...

PSivida CEO Invited To Speak At Surfaces In BioMaterials Foundation's BioInterface 2015 Annual Symposium

PSivida CEO Invited To Speak At Surfaces In BioMaterials Foundation's BioInterface 2015 Annual Symposium

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced Dr.

PSivida Corp Announces Fourth Quarter And Fiscal Year 2015 Financial Results Release Date And Conference Call Information

PSivida Corp Announces Fourth Quarter And Fiscal Year 2015 Financial Results Release Date And Conference Call Information

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that its financial results for the fourth quarter and fiscal year...

PSivida CEO To Speak At Controlled Release Society Annual Meeting Workshop In Edinburgh, Scotland, This Weekend

PSivida CEO To Speak At Controlled Release Society Annual Meeting Workshop In Edinburgh, Scotland, This Weekend

pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced Dr.